CCRF-CEM Electroporation Kit-Human Acute Lymphoblastic Leukemia's Peripheral Blood Cell
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 4 ml(Cat-655480) | Inquiry | Add to cart | |
| 30 ml(Cat-656606) | Inquiry | Add to cart |
Product Information
Modes of administration
Electroporation Efficiency:Electroporation kit provides 80-95% delivery efficiency of siRNA. Electroporation efficiency was determined by qRT-PCR.
Description
A 4-year-old Caucasian girl with acute lymphoblastic leukemia's peripheral blood was used to create the CCRF-CEM cell line in 1964. These tumor-causing cells have a T lymphoblast cell type and lymphoblast shape. With the exception of CD6, CCRF-CEM cells positively express CD3–CD7 antigens. These cells might be helpful in leukemia research transfection experiments. A human T-cell leukemia cell line known as CCRFCEM was first discovered in the peripheral blood of a person who had acute lymphoblastic leukemia. The mechanisms behind T-cell leukemia are frequently studied using these cells as a model system, as well as for screening possible anti-cancer medications. A great deal of the characteristics of T-cell leukemia cells, such as rapid proliferation, strong cytokine production, and the expression of T-cell surface markers, are known to be present in CCRF-CEM cells. In addition to examining the molecular mechanisms behind the onset and course of T-cell leukemia, researchers employ CCRF-CEM cells to assess the effectiveness of possible therapeutic agents. In the research of T-cell leukemia, CCRF-CEM cells are a useful tool that have helped us learn more about the condition and create new treatments.
